First Eagle Investment Management LLC lessened its holdings in shares of CareDx, Inc. (NASDAQ:CDNA – Free Report) by 58.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 493,582 shares of the company’s stock after selling 703,412 shares during the period. First Eagle Investment Management LLC’s holdings in CareDx were worth $32,083,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in CDNA. Nykredit A S purchased a new stake in CareDx during the second quarter worth approximately $25,000. Integrated Wealth Concepts LLC acquired a new position in CareDx in the second quarter valued at approximately $29,000. Reyes Financial Architecture Inc. acquired a new position in CareDx in the third quarter valued at approximately $50,000. Signaturefd LLC purchased a new position in CareDx in the third quarter valued at approximately $51,000. Finally, Allworth Financial LP purchased a new position in CareDx in the second quarter valued at approximately $72,000.
Analyst Ratings Changes
A number of research firms have weighed in on CDNA. HC Wainwright reissued a “neutral” rating and set a $46.00 price objective on shares of CareDx in a report on Friday, July 31st. Zacks Research upgraded shares of CareDx from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 5th. Weiss Ratings upgraded shares of CareDx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research report on Monday, August 3rd. Finally, Canaccord Genuity Group set a $99.00 price target on shares of CareDx in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, CareDx has a consensus rating of “Moderate Buy” and a consensus target price of $70.33.
Read Our Latest Research Report on CDNA
Insider Activity at CareDx
In other news, Director Michael Goldberg sold 13,800 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $79.15, for a total value of $1,092,270.00. Following the completion of the sale, the director directly owned 48,526 shares of the company’s stock, valued at approximately $3,840,832.90. This represents a 22.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Keith Kennedy sold 61,961 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $77.82, for a total value of $4,821,805.02. Following the completion of the sale, the chief financial officer directly owned 199,147 shares of the company’s stock, valued at $15,497,619.54. The trade was a 23.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 77,858 shares of company stock worth $6,080,346. 2.40% of the stock is currently owned by corporate insiders.
CareDx Stock Performance
CDNA opened at $74.56 on Wednesday. CareDx, Inc. has a one year low of $15.22 and a one year high of $90.87. The stock has a market capitalization of $3.92 billion, a P/E ratio of 111.70 and a beta of 2.51. The business’s 50-day simple moving average is $67.28 and its 200-day simple moving average is $37.24.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million during the quarter, compared to analysts’ expectations of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The business’s revenue was up 39.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS. On average, equities research analysts forecast that CareDx, Inc. will post 1.00 EPS for the current fiscal year.
CareDx Profile
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also
- Five stocks we like better than CareDx
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA – Free Report).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
